RESUMEN
The genome of Azoarcus olearius DQS-4T , a N2 -fixing Betaproteobacterium isolated from oil-contaminated soil in Taiwan, was sequenced and compared with other Azoarcus strains. The genome sequence showed high synteny with Azoarcus sp. BH72, a model endophytic diazotroph, but low synteny with five non-plant-associated strains (Azoarcus CIB, Azoarcus EBN1, Azoarcus KH32C, A. toluclasticus MF63T and Azoarcus PA01). Average Nucleotide Identity (ANI) revealed that DQS-4T shares 98.98% identity with Azoarcus BH72, which should now be included in the species A. olearius. The genome of DQS-4T contained several genes related to plant colonization and plant growth promotion, such as nitrogen fixation, plant adhesion and root surface colonization. In accordance with the presence of these genes, DQS-4T colonized rice (Oryza sativa) and Setaria viridis, where it was observed within the intercellular spaces and aerenchyma mainly of the roots. Although they promote the growth of grasses, the mechanism(s) of plant growth promotion by A. olearius strains is unknown, as the genomes of DQS-4T and BH72 do not contain genes for indole acetic acid (IAA) synthesis nor phosphate solubilization. In spite of its original source, both the genome and behaviour of DQS-4T suggest that it has the capacity to be an endophytic, nitrogen-fixing plant growth-promoting bacterium.
Asunto(s)
Azoarcus/genética , Azoarcus/metabolismo , Endófitos/genética , Genoma Bacteriano/genética , Oryza/crecimiento & desarrollo , Setaria (Planta)/crecimiento & desarrollo , Secuencia de Bases , Endófitos/metabolismo , Regulación Bacteriana de la Expresión Génica , Hierro/metabolismo , Fijación del Nitrógeno/fisiología , Oryza/microbiología , Análisis de Secuencia de ADN , Setaria (Planta)/microbiología , Microbiología del Suelo , Azufre/metabolismoRESUMEN
Hyperglycemia is associated with an increased risk of cardiovascular disease, and the consequences of intensive therapy may depend on the mechanism of the anti-diabetic agent(s) used to achieve a tight control. In animal models, stable analogues of glucagon-like peptide-1 (GLP-1) were able to reduce body weight and blood pressure and also had favorable effects on ischemia following coronary reperfusion. In a similar way, dipeptidyl peptidase IV (DPP-IV) showed to have favorable effects in animal models of ischemia/reperfusion. This could be due to the fact that DPP-IV inhibitors were able to prevent the breakdown of GLP-1 and glucose-dependent insulinotropic polypeptide, but they also decreased the degradation of several vasoactive peptides. Preclinical data for GLP-1, its derivatives and inhibitors of the DPP-IV enzyme degradation suggests that these agents may be able to, besides controlling glycaemia, induce cardio-protective and vasodilator effects. Notwithstanding the many favorable cardiovascular effects of GLP-1/incretins reported in different studies, many questions remain unanswered due the limited number of studies in human beings that aim to examine the effects of GLP-1 on cardiovascular endpoints. For this reason, long-term trials searching for positive cardiovascular effects are now in process, such as the CAROLINA and CARMELINA trials, which are supported by small pilot studies performed in humans (and many more animal studies) with incretin-based therapies. On the other hand, selective renal sodium-glucose co-transporter 2 inhibitors were also evaluated in the prevention of cardiovascular outcomes in type 2 diabetes. However, it is quite early to draw conclusions, since data on cardiovascular outcomes and cardiovascular death are limited and long-term studies are still ongoing. In this review, we will analyze the mechanisms underlying the cardiovascular effects of incretins and, at the same time, we will present a critical position about the real value of these compounds in the cardiovascular system and its protection.
RESUMEN
PURPOSE: We discuss the effectiveness, tolerability, and safety of vagus nerve stimulation (VNS) as adjunctive therapy in 26 patients with refractory epileptic encephalopathies (EEs). MATERIAL AND METHODS: Twenty-six patients (17 male and 9 female) with electroclinical features compatible with Lennox-Gastaut syndrome (LGS) in 20 patients, Dravet syndrome (DS) in 3 patients, and epilepsy with myoclonic-astatic seizures (EMAS) in 3 patients implanted with the NCP system were analyzed. RESULTS: In our series of patients with LGS, 17 cases showed a significant improvement in seizure control, with a reduction in seizure frequency of at least 50%. Seven of them previously had epileptic spasms. Three patients with EMAS and two patients with DS showed a significant improvement in seizure control, with a reduction in seizure frequency of at least 50%. A good clinical response was evident early and efficacy progressively improved with the duration of treatment up to 36 months. In patients who had a reduction in seizure frequency of at least 50%, quality of life (QOL) and neuropsychological performance improved. VNS was well-tolerated in all patients. CONCLUSION: VNS is an effective and well-tolerated treatment for patients with epileptic encephalopathies EEs, improving QOL and neuropsychological performance.
Asunto(s)
Epilepsia/terapia , Estimulación del Nervio Vago , Adolescente , Encefalopatías/complicaciones , Encefalopatías/terapia , Niño , Preescolar , Electrodos Implantados/efectos adversos , Epilepsia/complicaciones , Femenino , Humanos , Masculino , Pruebas Neuropsicológicas , Calidad de Vida , Estimulación del Nervio Vago/efectos adversos , Adulto JovenRESUMEN
We present a patient with cryptogenic focal epilepsy and another with Dravet syndrome, who experienced seizure aggravation and negative myoclonus, associated with continuous spikes and waves during slow sleep, induced by levetiracetam. For both patients levetiracetam was discontinued, and there was significant improvement of this particular electroclinical picture.
Asunto(s)
Anticonvulsivantes/efectos adversos , Electroencefalografía/efectos de los fármacos , Epilepsias Parciales/inducido químicamente , Epilepsias Parciales/tratamiento farmacológico , Epilepsia Tónico-Clónica/inducido químicamente , Epilepsia Tónico-Clónica/tratamiento farmacológico , Piracetam/análogos & derivados , Convulsiones/inducido químicamente , Sueño/efectos de los fármacos , Anticonvulsivantes/uso terapéutico , Niño , Quimioterapia Combinada , Epilepsias Mioclónicas/inducido químicamente , Epilepsias Mioclónicas/diagnóstico , Epilepsias Parciales/diagnóstico , Epilepsia Tónico-Clónica/diagnóstico , Potenciales Evocados/efectos de los fármacos , Femenino , Humanos , Levetiracetam , Masculino , Piracetam/efectos adversos , Piracetam/uso terapéutico , Convulsiones/diagnóstico , SíndromeRESUMEN
El síndrome opsoclonus- mioclonus es una rara entidad, que en niños se caracteriza por: irritabilidad, movimientos oculares caóticos con componentes verticales, horizontales, rotatorios (opsoclonus), mioclonus y ataxia. Se asocia en un alto porcentaje de casos con neuroblastoma aunque otras etiologías son también reconocidas (infecciosa-parainfecciosa, tóxicos). Un mecanismo autoinmune se considera responsable de la disfunción de estructuras en el tronco cerebral y cerebelo, que explicarían algunos de los síntomas cardinales (opsoclonus-mioclonus, ataxia). Sin embargo los signos de compromiso encefalopáticos y el elevado porcentaje de pacientes con secuelas neurocognitivas y psiquiátricas hablarían a favor de una disfunción más amplia. El tratamiento con esteroides, ACTH y drogas inmunomoduladoras e inmunosupresoras es actualmente utilizado, sin embargo es necesario realizar estudios prospectivos con protocolos terapéuticos uniformes para definir si el uso prolongado de estas drogas influencian favorablemente la evolución en este grupo de pacientes.
The opsoclonus-myoclonus syndrome in children is a rare entity which is characterized by irritability, chaotic ocular movements with vertical, horizontal, rotatory components (opsoclonus) along with myoclonus and ataxia. In a high proportion of cases, it is associated with neuroblastoma although other etiologies involving infectious or toxic agents have been reported. An autoimmune mechanism would be responsible for the dysfunction of structures in brain stem and cerebellum thus explaining some of the cardinal symptoms such as opsoclonus, myoclonus and ataxia. However, encephalopathic symptoms and the high percentage of patients with neurocognitive and psychiatric sequels are in favor of a wider dysfunction. Treatment with steroids, ACTH, immunomodulatory or immunosuppressive drugs is being used although prospective studies are needed to determine whether the prolonged use of these drugs influences favorably the evolution of these patients.